Research graph
References from Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19)
10.1002/dmrr.3377 · 2021 · External reference
Risk factors of severe cases with COVID-19: a meta-analysis
10.1017/s095026882000179x · 2020 · External reference
Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection
10.1007/s11255-020-02451-9 · 2020 · External reference
Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021
10.5888/pcd18.210123 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2 Delta and Omicron waves in the USA
10.1007/s40121-022-00755-0 · 2023 · External reference
Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19: a cohort study
10.7326/m22-1286 · 2023 · External reference
Real-world effectiveness of sotrovimab for the early treatment of COVID-19 in the US
2022 · External reference
10.1101/2023.03.09.23287034
10.1101/2023.03.09.23287034 · External reference
Unresolved reference
External reference
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
10.1136/bmj-2022-071932 · 2022 · External reference
Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants—United States, June 2021–January 2022
10.15585/mmwr.mm7106a4 · 2022 · External reference
Genomic surveillance for SARS-CoV-2 variants: circulation of Omicron lineages—United States, January 2022–May 2023
10.15585/mmwr.mm7224a2 · 2023 · External reference
Real-world clinical outcomes of bebtelovimab and sotrovimab treatment of high-risk persons with coronavirus disease 2019 during the Omicron epoch
10.1093/ofid/ofac411 · 2022 · External reference
A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate Coronavirus Disease-19: the Mayo Clinic Model
10.1016/j.mayocp.2021.03.010 · 2021 · External reference
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19
10.1172/jci151697 · 2021 · External reference
Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate Coronavirus Disease 2019
10.1093/infdis/jiab377 · 2021 · External reference
Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the Delta variant
10.1016/j.mayocp.2021.12.002 · 2022 · External reference
Casirivimab-imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
10.1016/j.eclinm.2021.101102 · 2021 · External reference
Comparable outcomes for bebtelovimab and ritonavir-boosted mirmatrelvir treatment in high-risk patinets with Coronavirus Disease-2019 during Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron epoch
10.1093/infdis/jiac346 · 2022 · External reference
Clinical prioritization of antispike monoclonal antibody treatment of mild to moderate COVID-19
10.1016/j.mayocp.2021.11.017 · 2022 · External reference
Impact of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19
10.1177/21501327211019282 · 2021 · External reference
Real-world evidence of the neutralizing monoclonal antibody sotrovimab for preventing hospitalization and mortality in COVID-19 outpatients
10.1093/infdis/jiac206 · 2022 · External reference
Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase
10.1016/j.ijid.2022.10.002 · 2023 · External reference
Curbing the Delta surge: clinical outcomes after treatment with bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab for mild to moderate coronavirus disease 2019
10.1016/j.mayocp.2022.06.015 · 2022 · External reference
10.1101/2022.12.30.22284063
10.1101/2022.12.30.22284063 · External reference
Unresolved reference
External reference
10.1101/2022.11.28.22282808
10.1101/2022.11.28.22282808 · External reference
Unresolved reference
External reference
Outcomes of COVID-19 with the Mayo Clinic model of care and research
10.1016/j.mayocp.2020.12.006 · 2021 · External reference
SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads
10.1016/j.xcrm.2022.100564 · 2022 · External reference
Unresolved reference
External reference
